A federal judge tossed a lawsuit by the US Federal Trade Commission on Thursday accusing Endo International Plc and Impax Laboratories of violating antitrust laws by striking a deal that stifled competition in the market for Opana ER, an opioid pain medication.
The reasons for US District Judge Royce Lamberth’s decision were not immediately clear, as the Washington, D.C.-based judge filed his opinion under seal to allow the parties five days to address whether anything should be redacted.
The decision marks a major setback for FTC antitrust enforcers, who had successfully pursued an earlier case, in 2017, against both drugmakers over the same drug.
The companies argued the deal at the center of the FTC’s latest case was not anticompetitive but rather a lawful licensing agreement that allowed both companies to compete.
The US Food and Drug Administration had asked Endo in June 2017 to pull its extended-release oxymorphone product off the market because of concerns that it was vulnerable to intravenous abuse, the FTC stated. That left Impax’s generic extended-release version of the medicine alone on the market. Rather than reformulate its drug, Endo struck a deal with Impax in August 2017 to refrain from re-entering the market, the FTC stated.
Endo, represented by George Gordon of Dechert, and Amneal Pharmaceuticals Inc, which now owns Impax and was represented by Devora Allon of Kirkland & Ellis, did not respond to requests for comment. The FTC declined to comment.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI